GTC
ENGN icon

Ghost Tree Capital’s enGene Therapeutics ENGN Stock Holding History

Ghost Tree Capital’s Portfolio ENGN Stock Details ENGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$1.06M Sell
160,898
-259,433
-62% -$1.93M 0.32% 53
2024
Q2 		$3.96M Buy
420,331
+220,331
+110% +$2.83M 1.24% 33
2024
Q1 		$3.39M Buy
+200,000
New +$2.45M 0.94% 36

Other funds holding ENGN

FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Ghost Tree Capital's ENGN Position: Q3 2024 in Review

Ghost Tree Capital reduced its enGene Therapeutics (ENGN) stake by 62% in Q3 2024, selling an estimated $1.93M and leaving 160,898 shares worth $1.06M. The position accounts for 0.32% of the portfolio, ranked #53.

Ghost Tree Capital first reported a position in ENGN in Q1 2024 and has held it in 3 quarters since. The position peaked at $3.96M in Q2 2024. 30 funds tracked by Wall St. Rank hold ENGN as of Q3 2024.

  • Ghost Tree Capital held 160,898 shares of enGene Therapeutics worth $1.06M as of Q3 2024.
  • Ghost Tree Capital sold 259,433 enGene Therapeutics shares in Q3 2024, an estimated $1.93M.
  • enGene Therapeutics made up 0.32% of Ghost Tree Capital's portfolio in Q3 2024, its #53 holding.
  • Ghost Tree Capital first reported a position in enGene Therapeutics in Q1 2024 and has held it in 3 quarters since.
  • Ghost Tree Capital's enGene Therapeutics position peaked at $3.96M in Q2 2024.
  • 30 funds tracked by Wall St. Rank held enGene Therapeutics as of Q3 2024.

Based on Ghost Tree Capital's 13F filing for Q3 2024, filed 14 Nov 2024.